This article was originally published in Pharmaceutical Approvals Monthly
A two-year study of 10 mg alendronate daily in 241 men with osteoporosis shows mean bone mineral density increases of 7.1±0.3% at the lumbar spine, 2.5±0.4% at the femoral neck, and 2.0±0.2% for the total body. Placebo patients saw a 1.8±0.5% increase in BMD at the lumbar spine and no significant changes in femoral neck or total body BMD, investigators reported in the New England Journal of Medicine Aug. 31. The results were similar to one-year data announced last fall. Merck has an sNDA with priority review status pending at FDA for treatment of male osteoporosi
You may also be interested in...
Emerging Company Profile: Aelix Therapeutics has constructed a potential therapeutic HIV vaccine to refocus the immune system onto vulnerable parts of the virus, and may allow patients to control viral replication without antiretroviral therapy.
Coherus BioSciences has sold a little under 2.5 million shares to partner Junshi Biosciences, giving the firm additional capital following a large debt financing last year.
A provisional list of CBD products that can continue to legally be sold in the UK has been issued by the Food Standards Agency. However the list currently only includes products from three suppliers and will not be complete until June 2021, meaning the vast majority of companies face a nervy wait.